Hypothesis

Senescent keratocytes accumulate with age and secrete a pro‑fibrotic secretome that up‑regulates lysyl oxidase (LOX) activity, leading to excessive collagen cross‑linking, stromal stiffening, and the observed decline in transparency. This positions cellular senescence, not simple keratocyte loss, as the primary driver of age‑related stromal pathology.

Mechanistic Rationale

• Keratocyte density declines linearly (~0.45%/yr) but histological studies show a disproportionate increase in p16^INK4a^‑positive cells in the anterior stroma after age 50, suggesting senescence expands relative to total cell loss.
• Senescent fibroblasts in other tissues secrete SASP factors (IL‑6, TGF‑β1, PDGF‑AA) that stimulate LOX transcription and secretion; LOX catalyzes lysine‑derived cross‑links that increase tensile strength and light scattering.
• The corneal stroma’s unique reliance on a highly ordered, low‑cross‑linked collagen lattice makes it especially vulnerable to even modest LOX up‑regulation, explaining the steep rise in stiffness from 67.9 kPa to >240 kPa with age.

Testable Predictions

1. Biomarker correlation – In human donor corneas stratified by age, the proportion of senescent keratocytes (p16^INK4a^ or SA‑β‑gal^+) will positively correlate with LOX activity (hydroxylysyl‑pyridinoline cross‑link levels) and stromal stiffness measured by Brillouin microscopy.
2. Causal link – Ex vivo culture of young corneal stroma treated with conditioned medium from senescent keratocytes will show increased LOX expression, elevated cross‑linking, and heightened stiffness compared to medium from non‑senescent keratocytes.
3. Intervention – Topical application of a senolytic (e.g., dasatinib + quercetin) to aged mouse corneas will reduce senescent keratocyte burden, lower LOX activity, partially restore stromal stiffness toward youthful values, and improve corneal transparency metrics (haze score, light transmission).
4. Refractive surgery interaction – Eyes undergoing LASIK will exhibit an accelerated rise in senescent keratocyte markers post‑operatively; prophylactic senolytic delivery will attenuate the post‑surgical increase in stromal stiffness and long‑term haze.

Falsifiability

• If senescent keratocyte density does not increase with age, or if LOX activity and stiffness remain unchanged after senolytic clearance, the hypothesis is falsified.
• If conditioned medium from senescent keratocytes fails to up‑regulate LOX or alter stiffness in young stroma, the proposed paracrine mechanism is invalid.
• If senolytic treatment does not improve biomechanical or optical outcomes despite reducing senescence markers, alternative drivers (e.g., oxidative glycation) must be considered.

Experimental Approach (brief)

• Human donor corneas (n=30, ages 20‑80) immunostained for p16^INK4a^, SA‑β‑gal, and LOX; quantify via image analysis; correlate with Brillouin‑derived stiffness and OCT‑based haze.
• Primary keratocytes isolated from young donors induced senescent via irradiation (10 Gy) or passaging; collect conditioned medium; apply to naïve stromal explants; measure LOX activity (fluorometric assay), cross‑link density (HPLC), and stiffness (AFM nanoindentation).
• Aged (12‑month) mice receive topical dasatinib + quercetin (5 mg/mL) twice weekly for 4 weeks; controls receive vehicle; assess senescent keratocyte burden, LOX, stiffness (nanoindentation), and in vivo confocal microscopy for haze.

Conclusion: By linking keratocyte senescence to enzymatic collagen cross‑linking, this hypothesis reframes age‑related corneal stiffening as a potentially reversible, secretory‑driven process, opening a therapeutic avenue with senolytics to preserve vision.